Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 241 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Control Form 6 Clear all
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Pumpkin Seed Oil Supplementation on Cardiovascular Function in Postmenopausal Women.

NCT03716960
View directory record Official record
Conditions
Elevated Blood Pressure, Hypertension
Interventions
Pumpkin Seed Oil, Placebo
Other
Lead sponsor
Marymount University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 11, 2026, 5:15 PM EDT
Terminated Phase 2 Interventional Results available

VB-111 in Surgically Accessible Recurrent/Progressive GBM

NCT04406272
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma
Interventions
VB11, Surgery, Placebo, Bevacizumab
Drug · Procedure · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 11, 2026, 5:15 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Topical Cannabidiol Cream and Post-exercise Recovery

NCT05044936
View directory record Official record
Conditions
Muscle Damage
Interventions
Cannabidiol Oil, Resistance Exercise
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 11, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

NCT03078751
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Adjuvant endocrine therapy, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
33
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 11, 2026, 5:15 PM EDT
Completed Phase 4 Interventional Results available

Are Opioids Needed After ACL Reconstruction

NCT04285853
View directory record Official record
Conditions
Anterior Cruciate Ligament Rupture
Interventions
Oxycodone, Placebo oral tablet
Drug
Lead sponsor
Emory University
Other
Eligibility
14 Years to 40 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia • Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 11, 2026, 5:15 PM EDT
Withdrawn Phase 2 Interventional

The Effectiveness of Lower Cyclosporine Doses for Psoriasis

NCT00377325
View directory record Official record
Conditions
Psoriasis
Interventions
Cyclosporine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 11, 2026, 5:15 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis

NCT04123795
View directory record Official record
Conditions
Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
Interventions
Certolizumab pegol, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
6 Years to 17 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 11, 2026, 5:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle GI Health: A Study of Health and Wellness Products on GI Health and Other Health Outcomes

NCT06009614
View directory record Official record
Conditions
Digestion, Abdominal Pain, GI Disorders
Interventions
Radicle GI Health Placebo Control Form 1, Radicle GI Health Active Study Product 1.1 Usage, Radicle GI Health Placebo Control Form 2, Radicle GI Health Active Study Product 2.1 Usage, Radicle GI Health Active Study Product 2.2 Usage, Radicle GI Health Placebo Control Form 3, Radicle GI Health Active Study Product 3.1 Usage
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
2,180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated May 19, 2024 · Synced Sep 11, 2026, 5:15 PM EDT
Active, not recruiting Phase 2 Interventional

This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC

NCT07723924
View directory record Official record
Conditions
Functional Constipation (FC)
Interventions
plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 11, 2026, 5:15 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

NCT01473524
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
15
States / cities
Sacramento, California • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 11, 2026, 5:15 PM EDT
Completed Phase 3 Interventional Results available

A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)

NCT01604343
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Sirukumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
48
States / cities
Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Sep 11, 2026, 5:15 PM EDT
Completed Not applicable Interventional Results available

The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse

NCT01987089
View directory record Official record
Conditions
Insomnia
Interventions
Cognitive Behavioral Therapy for Insomnia (CBT-I)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Sep 11, 2026, 5:15 PM EDT
Terminated Phase 4 Interventional Results available

Reduction in Symptomatic Esophageal Stricture Formation

NCT02039115
View directory record Official record
Conditions
Esophageal Stenosis
Interventions
prednisone, placebo
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Sep 11, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Two Types of Treatment in Restoring Muscle After Hip or Knee Surgery

NCT00393848
View directory record Official record
Conditions
Hip Fracture, Osteoarthritis, Femur Head Necrosis
Interventions
Essential amino acid supplement, Ketoconazole, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
30 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 11, 2026, 5:15 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

NCT01994291
View directory record Official record
Conditions
Macular Edema, Diabetic
Interventions
Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 11, 2026, 5:15 PM EDT
Completed Phase 3 Interventional Results available

A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis

NCT02692391
View directory record Official record
Conditions
Acute Pancreatitis
Interventions
Indomethacin, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 11, 2026, 5:15 PM EDT
Completed Phase 4 Interventional Results available

The Health Influences of Puberty (HIP) Study

NCT01775813
View directory record Official record
Conditions
Obesity, Insulin Resistance, Gonadal Dysfunction, Type 2 Diabetes
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 11, 2026, 5:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

NCT00983255
View directory record Official record
Conditions
Bacterial Infections
Interventions
TR-701 FA for injection, 200 mg/vial, TR-701 FA tablets
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 11, 2026, 5:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children

NCT01459198
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MEDI ΔM2-2 vaccine, Placebo vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Sep 11, 2026, 5:15 PM EDT
Completed Phase 1 Interventional

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

NCT02830542
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
SER-262, Placebo
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Athens, Alabama • Fountain Valley, California • La Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Sep 11, 2026, 5:15 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation

NCT07323446
View directory record Official record
Conditions
Emotional Dysregulation
Interventions
N-Acetyl Cysteine (NAC), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 11, 2026, 5:15 PM EDT
Recruiting Not applicable Interventional

The Role of Knowledge Retrieval in Inference-making

NCT05692973
View directory record Official record
Conditions
Reading Disability, Reading Problem
Interventions
Role of Knowledge Retrieval, Inference Intervention
Behavioral
Lead sponsor
William Jewell College
Other
Eligibility
8 Years to 14 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Excelsior Springs, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 11, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

Study of the Medication Prazosin for Alcohol Dependence

NCT00762710
View directory record Official record
Conditions
Alcoholism
Interventions
Prazosin medication, Placebo medication
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 11, 2026, 5:15 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

NCT03345914
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Sep 11, 2026, 5:15 PM EDT